Yang Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yang Yu has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Ming-Tao Zhao
Center for Cardiovascular Research, Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH 43205, USA
6 shared publications - Vidu Garg
Department of Pediatrics The Ohio State University College of Medicine Columbus Ohio USA
5 shared publications - Cankun Wang
Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, USA
4 shared publications - Qin Ma
The Ohio State University
4 shared publications - Alexander William Charney
Icahn School of Medicine at Mount Sinai
3 shared publications Alice Hashemi
Charles Bronfman Institute for Personalized Medicine, Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, USA
3 shared publications
Latest Publications
- Open Access
Live-Cell Monitoring and Transcriptomic Profiling Identify Distinct Temporal Patterns of Cell-Cycle Activity and Maturation in Human iPSC-Derived Cardiomyocytes
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) show decreasing cell-cycle activity during prolonged culture. However, it remains unclear whether changes in cell-cycle activity occur before, after, or concurrently with transcriptional changes in cell-cycle and maturation-associated programs. Here, we combined a TNNT2-FUCCI reporter, Ki67 immunostaining, and bulk RNA sequencing to define how cell-cycle activity changes during prolonged human iPSC-cardiomyocyte culture. FUCCI and Ki67 analyses showed similar levels of cell-cycle activity at days 20 and 30 of cardiomyocyte differentiation but declined more clearly by day 40. In contrast, transcriptomic profiling revealed that canonical cell-cycle and DNA-replication programs were already reduced by day 30. The subsequent day-30-to-day-40 interval was characterized by increased expression of sarcomeric, contractile, and calcium-handling gene programs rather than a further broad loss of mitotic pathways. These findings support a staged model of human iPSC-cardiomyocyte maturation-associated transcriptional remodeling in which a reduction in cell-cycle-associated transcription is detectable before the subsequent decline in cardiomyocyte cell-cycle activity, thereby identifying distinct temporal patterns of cell-cycle and maturation-associated changes during prolonged hiPSC-CM culture.
Open AccessLive-Cell Monitoring and Transcriptomic Profiling Identify Distinct Temporal Patterns of Cell-Cycle Activity and Maturation in Human iPSC-Derived Cardiomyocytes
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) show decreasing cell-cycle activity during prolonged culture. However, it remains unclear whether changes in cell-cycle activity occur before, after, or concurrently with transcriptional changes in cell-cycle and maturation-associated programs. Here, we combined a TNNT2-FUCCI reporter, Ki67 immunostaining, and bulk RNA sequencing to define how cell-cycle activity changes during prolonged human iPSC-cardiomyocyte culture. FUCCI and Ki67 analyses showed similar levels of cell-cycle activity at days 20 and 30 of cardiomyocyte differentiation but declined more clearly by day 40. In contrast, transcriptomic profiling revealed that canonical cell-cycle and DNA-replication programs were already reduced by day 30. The subsequent day-30-to-day-40 interval was characterized by increased expression of sarcomeric, contractile, and calcium-handling gene programs rather than a further broad loss of mitotic pathways. These findings support a staged model of human iPSC-cardiomyocyte maturation-associated transcriptional remodeling in which a reduction in cell-cycle-associated transcription is detectable before the subsequent decline in cardiomyocyte cell-cycle activity, thereby identifying distinct temporal patterns of cell-cycle and maturation-associated changes during prolonged hiPSC-CM culture.
- Open Access
- 4 March 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (11) , 1878
Author Correction: Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
- 4 March 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (11) , 1878
Open AccessAuthor Correction: Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
- Top Cited Papers
- 17 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (10) , 1653-1663
Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system
The systemic delivery of mRNA molecules to the central nervous system is challenging as they need to cross the blood–brain barrier (BBB) to reach into the brain. Here we design and synthesize 72 BBB-crossing lipids fabricated by conjugating BBB-crossing modules and amino lipids, and use them to assemble BBB-crossing lipid nanoparticles for mRNA delivery. Screening and structure optimization studies resulted in a lead formulation that has substantially higher mRNA delivery efficiency into the brain than those exhibited by FDA-approved lipid nanoparticles. Studies in distinct mouse models show that these BBB-crossing lipid nanoparticles can transfect neurons and astrocytes of the whole brain after intravenous injections, being well tolerated across several dosage regimens. Moreover, these nanoparticles can deliver mRNA to human brain ex vivo samples. Overall, these BBB-crossing lipid nanoparticles deliver mRNA to neurons and astrocytes in broad brain regions, thereby being a promising platform to treat a range of central nervous system diseases.
- 17 February 2025
- Published by Springer Nature in Nature Materials
- Vol. 24 (10) , 1653-1663
Top Cited PapersBlood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system
The systemic delivery of mRNA molecules to the central nervous system is challenging as they need to cross the blood–brain barrier (BBB) to reach into the brain. Here we design and synthesize 72 BBB-crossing lipids fabricated by conjugating BBB-crossing modules and amino lipids, and use them to assemble BBB-crossing lipid nanoparticles for mRNA delivery. Screening and structure optimization studies resulted in a lead formulation that has substantially higher mRNA delivery efficiency into the brain than those exhibited by FDA-approved lipid nanoparticles. Studies in distinct mouse models show that these BBB-crossing lipid nanoparticles can transfect neurons and astrocytes of the whole brain after intravenous injections, being well tolerated across several dosage regimens. Moreover, these nanoparticles can deliver mRNA to human brain ex vivo samples. Overall, these BBB-crossing lipid nanoparticles deliver mRNA to neurons and astrocytes in broad brain regions, thereby being a promising platform to treat a range of central nervous system diseases.
- 25 November 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (11) , 1783-1789
Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
Delivery of biomacromolecules to the central nervous system (CNS) remains challenging because of the restrictive nature of the blood–brain barrier (BBB). We developed a BBB-crossing conjugate (BCC) system that facilitates delivery into the CNS through γ-secretase-mediated transcytosis. Intravenous administration of a BCC10–oligonucleotide conjugate demonstrated effective transportation of the oligonucleotide across the BBB and gene silencing in wild-type mice, human brain tissues and an amyotrophic lateral sclerosis mouse model.
- 25 November 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (11) , 1783-1789
Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
Delivery of biomacromolecules to the central nervous system (CNS) remains challenging because of the restrictive nature of the blood–brain barrier (BBB). We developed a BBB-crossing conjugate (BCC) system that facilitates delivery into the CNS through γ-secretase-mediated transcytosis. Intravenous administration of a BCC10–oligonucleotide conjugate demonstrated effective transportation of the oligonucleotide across the BBB and gene silencing in wild-type mice, human brain tissues and an amyotrophic lateral sclerosis mouse model.
- Open Access
- 25 October 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (10) , 1021-1024
Cell-Free RNA Signatures in Maternal Blood with Fetal Congenital Heart Disease
- 25 October 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (10) , 1021-1024
Open AccessCell-Free RNA Signatures in Maternal Blood with Fetal Congenital Heart Disease
- 12 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (11) , 888-891
Abnormal Progenitor Cell Differentiation and Cardiomyocyte Proliferation in Hypoplastic Right Heart Syndrome
- 12 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (11) , 888-891
Abnormal Progenitor Cell Differentiation and Cardiomyocyte Proliferation in Hypoplastic Right Heart Syndrome
- Open Access
- 13 December 2023
- Published by Elsevier in Stem Cell Research
- Vol. 74, 103281
Generation and characterization of a human induced pluripotent stem cell line heterozygous for a NOTCH1 mutation (NCHi014-A)
- 13 December 2023
- Published by Elsevier in Stem Cell Research
- Vol. 74, 103281
Open AccessGeneration and characterization of a human induced pluripotent stem cell line heterozygous for a NOTCH1 mutation (NCHi014-A)
- 4 August 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (Suppl_1)
Abstract P1029: Abnormal Progenitor Cell Differentiation And Cardiomyocyte Proliferation In Hypoplastic Right Heart Syndrome
- 4 August 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 133 (Suppl_1)
Abstract P1029: Abnormal Progenitor Cell Differentiation And Cardiomyocyte Proliferation In Hypoplastic Right Heart Syndrome
- Open Access
- 20 January 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 132 (2) , 187-204
Impaired Human Cardiac Cell Development due to NOTCH1 Deficiency
Background: NOTCH1 pathogenic variants are implicated in multiple types of congenital heart defects including hypoplastic left heart syndrome, where the left ventricle is underdeveloped. It is unknown how NOTCH1 regulates human cardiac cell lineage determination and cardiomyocyte proliferation. In addition, mechanisms by which NOTCH1 pathogenic variants lead to ventricular hypoplasia in hypoplastic left heart syndrome remain elusive. Methods: CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 genome editing was utilized to delete NOTCH1 in human induced pluripotent stem cells. Cardiac differentiation was carried out by sequential modulation of WNT signaling, and NOTCH1 knockout and wild-type differentiating cells were collected at day 0, 2, 5, 10, 14, and 30 for single-cell RNA-seq. Results: Human NOTCH1 knockout induced pluripotent stem cells are able to generate functional cardiomyocytes and endothelial cells, suggesting that NOTCH1 is not required for mesoderm differentiation and cardiovascular development in vitro. However, disruption of NOTCH1 blocks human ventricular-like cardiomyocyte differentiation but promotes atrial-like cardiomyocyte generation through shortening the action potential duration. NOTCH1 deficiency leads to defective proliferation of early human cardiomyocytes, and transcriptomic analysis indicates that pathways involved in cell cycle progression and mitosis are downregulated in NOTCH1 knockout cardiomyocytes. Single-cell transcriptomic analysis reveals abnormal cell lineage determination of cardiac mesoderm, which is manifested by the biased differentiation toward epicardial and second heart field progenitors at the expense of first heart field progenitors in NOTCH1 knockout cell populations. Conclusions: NOTCH1 is essential for human ventricular-like cardiomyocyte differentiation and proliferation through balancing cell fate determination of cardiac mesoderm and modulating cell cycle progression. Because first heart field progenitors primarily contribute to the left ventricle, we speculate that pathogenic NOTCH1 variants lead to biased differentiation of first heart field progenitors, blocked ventricular-like cardiomyocyte differentiation, and defective cardiomyocyte proliferation, which collaboratively contribute to left ventricular hypoplasia in hypoplastic left heart syndrome.
- 20 January 2023
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 132 (2) , 187-204
Open AccessImpaired Human Cardiac Cell Development due to NOTCH1 Deficiency
Background: NOTCH1 pathogenic variants are implicated in multiple types of congenital heart defects including hypoplastic left heart syndrome, where the left ventricle is underdeveloped. It is unknown how NOTCH1 regulates human cardiac cell lineage determination and cardiomyocyte proliferation. In addition, mechanisms by which NOTCH1 pathogenic variants lead to ventricular hypoplasia in hypoplastic left heart syndrome remain elusive. Methods: CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 genome editing was utilized to delete NOTCH1 in human induced pluripotent stem cells. Cardiac differentiation was carried out by sequential modulation of WNT signaling, and NOTCH1 knockout and wild-type differentiating cells were collected at day 0, 2, 5, 10, 14, and 30 for single-cell RNA-seq. Results: Human NOTCH1 knockout induced pluripotent stem cells are able to generate functional cardiomyocytes and endothelial cells, suggesting that NOTCH1 is not required for mesoderm differentiation and cardiovascular development in vitro. However, disruption of NOTCH1 blocks human ventricular-like cardiomyocyte differentiation but promotes atrial-like cardiomyocyte generation through shortening the action potential duration. NOTCH1 deficiency leads to defective proliferation of early human cardiomyocytes, and transcriptomic analysis indicates that pathways involved in cell cycle progression and mitosis are downregulated in NOTCH1 knockout cardiomyocytes. Single-cell transcriptomic analysis reveals abnormal cell lineage determination of cardiac mesoderm, which is manifested by the biased differentiation toward epicardial and second heart field progenitors at the expense of first heart field progenitors in NOTCH1 knockout cell populations. Conclusions: NOTCH1 is essential for human ventricular-like cardiomyocyte differentiation and proliferation through balancing cell fate determination of cardiac mesoderm and modulating cell cycle progression. Because first heart field progenitors primarily contribute to the left ventricle, we speculate that pathogenic NOTCH1 variants lead to biased differentiation of first heart field progenitors, blocked ventricular-like cardiomyocyte differentiation, and defective cardiomyocyte proliferation, which collaboratively contribute to left ventricular hypoplasia in hypoplastic left heart syndrome.
- Open Access
- 4 January 2023
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 25, e5
Precision medicine for long QT syndrome: patient-specific iPSCs take the lead
Long QT syndrome (LQTS) is a detrimental arrhythmia syndrome mainly caused by dysregulated expression or aberrant function of ion channels. The major clinical symptoms of ventricular arrhythmia, palpitations and syncope vary among LQTS subtypes. Susceptibility to malignant arrhythmia is a result of delayed repolarisation of the cardiomyocyte action potential (AP). There are 17 distinct subtypes of LQTS linked to 15 autosomal dominant genes with monogenic mutations. However, due to the presence of modifier genes, the identical mutation may result in completely different clinical manifestations in different carriers. In this review, we describe the roles of various ion channels in orchestrating APs and discuss molecular aetiologies of various types of LQTS. We highlight the usage of patient-specific induced pluripotent stem cell (iPSC) models in characterising fundamental mechanisms associated with LQTS. To mitigate the outcomes of LQTS, treatment strategies are initially focused on small molecules targeting ion channel activities. Next-generation treatments will reap the benefits from development of LQTS patient-specific iPSC platform, which is bolstered by the state-of-the-art technologies including whole-genome sequencing, CRISPR genome editing and machine learning. Deep phenotyping and high-throughput drug testing using LQTS patient-specific cardiomyocytes herald the upcoming precision medicine in LQTS.
- 4 January 2023
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 25, e5
Open AccessPrecision medicine for long QT syndrome: patient-specific iPSCs take the lead
Long QT syndrome (LQTS) is a detrimental arrhythmia syndrome mainly caused by dysregulated expression or aberrant function of ion channels. The major clinical symptoms of ventricular arrhythmia, palpitations and syncope vary among LQTS subtypes. Susceptibility to malignant arrhythmia is a result of delayed repolarisation of the cardiomyocyte action potential (AP). There are 17 distinct subtypes of LQTS linked to 15 autosomal dominant genes with monogenic mutations. However, due to the presence of modifier genes, the identical mutation may result in completely different clinical manifestations in different carriers. In this review, we describe the roles of various ion channels in orchestrating APs and discuss molecular aetiologies of various types of LQTS. We highlight the usage of patient-specific induced pluripotent stem cell (iPSC) models in characterising fundamental mechanisms associated with LQTS. To mitigate the outcomes of LQTS, treatment strategies are initially focused on small molecules targeting ion channel activities. Next-generation treatments will reap the benefits from development of LQTS patient-specific iPSC platform, which is bolstered by the state-of-the-art technologies including whole-genome sequencing, CRISPR genome editing and machine learning. Deep phenotyping and high-throughput drug testing using LQTS patient-specific cardiomyocytes herald the upcoming precision medicine in LQTS.